Phenylalpha

Phenylalpha

phenylephrine

Manufacturer:

Laboratoire Aguettant

Distributor:

HK Medical Supplies

Marketer:

Aguettant
Concise Prescribing Info
Contents
Phenylephrine HCl
Indications/Uses
Hypotension during spinal, epidural or general anesth.
Dosage/Direction for Use
Adult IV bolus 50-100 mcg, repeat until desired effect is attained. Max bolus dose: 100 mcg. Continuous infusion 25-50 mcg/min, increase or decrease dose to maintain systolic BP close to normal value.
Contraindications
Hypersensitivity. Combination w/ non-selective MAOIs (or w/in 2 wk of their w/drawal). Patients w/ severe HTN or peripheral vascular disease; severe hyperthyroidism.
Special Precautions
Monitor arterial BP during treatment. Closely monitor vital organ functions & consider dose reduction when systemic BP is near the lower end of target range in patients w/ reduced cardiac output or coronary vascular disease. May cause deterioration in heart failure as a consequence of induced vasoconstriction in patients w/ serious heart failure or cardiogenic shock. Avoid extravasation; may cause tissue necrosis. Patients w/ DM; arterial HTN; uncontrolled hyperthyroidism; CHD & chronic heart conditions; non-severe peripheral vascular insufficiency; bradycardia; partial heart block; tachycardia; arrhythmias; angina pectoris; aneurysma; closed angle glaucoma; arteriosclerosis; impaired cerebral or coronary circulation; patients on controlled Na diet. Patients w/ renal or hepatic impairment. Pregnancy & lactation. May potentially cause fetal hypoxia & bradycardia if administered in late pregnancy or labour. Elderly. Childn.
Adverse Reactions
Bradycardia, hypertensive episodes, nausea & vomiting.
Drug Interactions
Paroxysmal HTN & hyperthermia w/ non-selective MAOI (eg, iproniazid, nialamide). Risk of vasoconstriction &/or hypertensive crisis w/ dopaminergic ergot alkaloids (bromocriptine, cabergoline, lisuride, pergolide); vasoconstrictor ergot alkaloids (dihydroergotamine, ergotamine, methylergometrine, methylsergide); selective type A MAOIs (moclobemide, toloxatone); linezolid. Paroxysmal HTN w/ possibility of arrhythmias w/ TCAs (eg, imipramine); noradrenergic-serotoninergic antidepressants (minalcipram, venlafaxine); sibutramine. Substantial BP increase w/ guanethidine & related products. Increased risk of arrhythmias w/ cardiac glycosides, quinidine. Risk of perioperative hypertensive crisis & arrhythmia w/ halogenated volatile anaesth (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane). Potentiated effect of presso-active sympathomimetic amines w/ oxytocic agents; severe persistent HTN & strokes can occur during post-partum period.
MIMS Class
ATC Classification
C01CA06 - phenylephrine ; Belongs to the class of adrenergic and dopaminergic cardiac stimulants excluding glycosides. Used in the treatment of hypotension.
Presentation/Packing
Form
Phenylalpha soln for inj 500 mcg/10 mL
Packing/Price
10 mL x 10 × 1's
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign up for free
Already a member? Sign in